Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Targeting TGF-β Signaling for Therapeutic Gain

(2017) Rosemary J. Akhurst   Cold Spring Harbor Perspectives in Biology

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

(2017) Jonathan M. Yingling et al.   Oncotarget

Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer

(2017) V. P. Baklaushev et al.   Scientific Reports

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer

(2015) Christine Mall et al.   OncoImmunology

Neutralizing Murine TGF R2 Promotes a Differentiated Tumor Cell Phenotype and Inhibits Pancreatic Cancer Metastasis

(2014) K. T. Ostapoff et al.   CANCER RESEARCH

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

(2014) Jordi Rodon et al.   CLINICAL CANCER RESEARCH

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Monoclonal antibody therapies targeting immune checkpoints induce fatal anaphylactic reactions in a murine model of breast cancer

(2014) Christine Mall et al.   Journal for ImmunoTherapy of Cancer

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

(2013) Ivelina Gueorguieva et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment

(2013) Brent A. Hanks et al.   JOURNAL OF CLINICAL INVESTIGATION

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Truncated Form of TGF- RII, But Not Its Absence, Induces Memory CD8+ T Cell Expansion and Lymphoproliferative Disorder in Mice

(2013) H. Ishigame et al.   JOURNAL OF IMMUNOLOGY

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Deletion of TGF-  signaling in myeloid cells enhances their anti-tumorigenic properties

(2012) S. V. Novitskiy et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Targeting the TGFβ signalling pathway in disease

(2012) Rosemary J. Akhurst et al.   NATURE REVIEWS DRUG DISCOVERY

Blockade of TGF-  Signaling by the TGF R-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma

(2011) M. Zhang et al.   CANCER RESEARCH

Anti-Transforming Growth Factor   Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

(2010) Z. Zhong et al.   CLINICAL CANCER RESEARCH

Targeting the Transforming Growth Factor-β pathway inhibits human basal-like breast cancer metastasis

(2010) Vidya Ganapathy et al.   Molecular Cancer

Platelet-Derived Transforming Growth Factor-  Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity

(2009) H.-G. Kopp et al.   CANCER RESEARCH

Targeting the transforming growth factor-β signaling pathway in human cancer

(2009) Nagathihalli S Nagaraj et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

(2008) Li Yang et al.   CANCER CELL

TGF-β: A Master of All T Cell Trades

(2008) Ming O. Li et al.   CELL

TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4

(2008) David Padua et al.   CELL

TGFβ in Cancer

(2008) Joan Massagué   CELL

LY2109761, a novel transforming growth factor   receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

(2008) D. Melisi et al.   MOLECULAR CANCER THERAPEUTICS